Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

NCT04470674 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of Accrual

Conditions

Lung Cancer
Non-small Cell Lung Cancer
PD-L1 Gene Mutation
KRAS Activating Mutation

Interventions

DRUG: Durvalumab
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Shirish M Gadgeel

Collaborators

[object Object]
[object Object]